Treatment of schizophrenia: towards a comprehensive approach
- (16/10/2007)
Satellite Symposium on the occasion of the 20th European College of Neuropsychopharmacology (ECNP) Congress supported by an unrestricted grant from Organon International Inc
Robin Murray, Jim van Os, Brian Kirkpatrick
Satellite Symposium on the occasion of the 20th European College of Neuropsychopharmacology (ECNP) Congress supported by an unrestricted grant from Organon International Inc
Robin Murray, Jim van Os, Brian Kirkpatrick
Depression, cortisol and new opportunities for treatments
- (4/4/2007)
Depression is usually characterized by an over activity of the hypothalamic-pituitary-adrenal (HPA) axis that resembles the neuro-endocrine response to stress. I hope to convince you that HPA axis hyperactivity is a crucial biological mechanism in the ...
Carmine M. Pariante MD, MRCPsych, PhD
Depression is usually characterized by an over activity of the hypothalamic-pituitary-adrenal (HPA) axis that resembles the neuro-endocrine response to stress. I hope to convince you that HPA axis hyperactivity is a crucial biological mechanism in the ...
Carmine M. Pariante MD, MRCPsych, PhD
Negative Symptoms and Schizophrenia: Recognition, Measurement and Treatment
- (11/11/2006)
An international panel of experts in schizophrenia has recently presented at an educational meeting focused on negative symptoms. These presentations can be viewed with the opportunity to earn continuing medical education credits.
International panel of experts in schizophrenia
An international panel of experts in schizophrenia has recently presented at an educational meeting focused on negative symptoms. These presentations can be viewed with the opportunity to earn continuing medical education credits.
International panel of experts in schizophrenia
Major Depressive Disorder and Insomnia: neurobiological and clinical interface
- (1/10/2006)
The goal of the program is to raise awareness of the strong relationship between major depressive disorder and insomnia and the implications of insomnia on the management of depression.
Rafael J Salin-Pascual MD, Ph.D.
The goal of the program is to raise awareness of the strong relationship between major depressive disorder and insomnia and the implications of insomnia on the management of depression.
Rafael J Salin-Pascual MD, Ph.D.
Antidepressants and suicidal behaviour: what is the best available evidence?
- (1/6/2006)
The possibility that antidepressant medication could actually contribute to suicidal behaviours has raised professional community concerns and resulted in widespread critical media comment. In this program Prof. Robert Goldney reviews the best available ...
Professor Robert Goldney
The possibility that antidepressant medication could actually contribute to suicidal behaviours has raised professional community concerns and resulted in widespread critical media comment. In this program Prof. Robert Goldney reviews the best available ...
Professor Robert Goldney
Treatment options to increase remission rates. Toward Remission in Depression: Are Dual-Action Drugs Superior to SSRIs?
- (1/3/2006)
The goal of the program is to raise awareness of the importance of achieving remission and the better long-term outcomes associated with remission, and to review evidence of therapeutic strategies for achieving remission.
Michael E. Thase, M.D.
The goal of the program is to raise awareness of the importance of achieving remission and the better long-term outcomes associated with remission, and to review evidence of therapeutic strategies for achieving remission.
Michael E. Thase, M.D.
How to combine antidepressant treatments?
- (1/1/2006)
If an initial antidepressant treatment fails to achieve an adequate improvement and dose increase is not successful, the next step is to add a second agent or switch to another agent. The clear advantages of combination/augmentation include maintenance of ...
Prof. Pierre Blier
If an initial antidepressant treatment fails to achieve an adequate improvement and dose increase is not successful, the next step is to add a second agent or switch to another agent. The clear advantages of combination/augmentation include maintenance of ...
Prof. Pierre Blier
How to adapt antidepressant treatment?
- (12/1/2005)
One strategy to improve patient outcome would be to adapt ineffective treatment earlier. However a prerequisite to this approach is knowing when and how to adapt treatment. In the previous two lectures, Prof. Armin Szegedi addressed ‘when’, presenting ...
Prof. Pierre Blier
One strategy to improve patient outcome would be to adapt ineffective treatment earlier. However a prerequisite to this approach is knowing when and how to adapt treatment. In the previous two lectures, Prof. Armin Szegedi addressed ‘when’, presenting ...
Prof. Pierre Blier
When to adapt antidepressant treatment?
- (11/7/2005)
In order to know when to adapt treatment, it must be possible to predict treatment outcome at a certain moment during the treatment course. Obviously the earlier outcome can be reliably predicted the better. In the first part of this presentation, partial ...
Professor Dr. Armin Szegedi
In order to know when to adapt treatment, it must be possible to predict treatment outcome at a certain moment during the treatment course. Obviously the earlier outcome can be reliably predicted the better. In the first part of this presentation, partial ...
Professor Dr. Armin Szegedi
How to predict outcome of antidepressant treatment?
- (11/5/2005)
Full remission - the ultimate goal of treatment – is not achieved by all patients following an acute trial of antidepressant treatment. As reliable predictors of response and remission prior to initiating pharmacotherapy have not yet been established, a ...
Professor Dr. Armin Szegedi
Full remission - the ultimate goal of treatment – is not achieved by all patients following an acute trial of antidepressant treatment. As reliable predictors of response and remission prior to initiating pharmacotherapy have not yet been established, a ...
Professor Dr. Armin Szegedi
 |
This site is intended for healthcare professionals outside the USA |  |
| Copyright © 2011 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved. | ||